Targeting CD56 with an antibody-drug conjugate in Merkel cell carcinoma

Br J Dermatol. 2022 Feb;186(2):209-210. doi: 10.1111/bjd.20894. Epub 2021 Nov 24.

Authors

L Leiendecker^{1

2}, P S Jung^{1

2

3}, A C Obenauf¹

Affiliations

¹ Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Campus-Vienna-BioCenter 1, Vienna, 1030, Austria.
² Vienna BioCenter PhD Program, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, 1030, Austria.
³ Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Abstract

Linked Article: Esnault et al. Br J Dermatol 2022; 186:295–306.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biomarkers, Tumor
Carcinoma, Merkel Cell* / drug therapy
Carcinoma, Merkel Cell* / pathology
Humans
Immunoconjugates* / therapeutic use
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology

Substances

Biomarkers, Tumor
Immunoconjugates